Evolus: Extra Strength Dose Data Provides Additional Offering Expansion For JeuveauSeeking Alpha • 02/07/23
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month PerformanceBusiness Wire • 01/28/23
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World CongressBusiness Wire • 01/23/23
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue AspirationBusiness Wire • 01/18/23
Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc.PRNewsWire • 12/07/22
Evolus Broadens Its International Presence with Nuceiva® Launch in Great BritainBusiness Wire • 10/04/22
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022Business Wire • 09/21/22
Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceBusiness Wire • 08/29/22
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®Business Wire • 08/24/22
Evolus, Inc. (EOLS) CEO David Moatazedi on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/02/22
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”Business Wire • 07/19/22